Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 4.36
NAS:OCUL's Cash-to-Debt is ranked lower than
63% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. NAS:OCUL: 4.36 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:OCUL' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.36  Med: 5.87 Max: 7.13
Current: 4.36
4.36
7.13
Equity-to-Asset 0.69
NAS:OCUL's Equity-to-Asset is ranked higher than
52% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. NAS:OCUL: 0.69 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:OCUL' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.84  Med: 0.72 Max: 0.81
Current: 0.69
-1.84
0.81
Piotroski F-Score: 2
Altman Z-Score: 2.89
Beneish M-Score: 1.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -2296.03
NAS:OCUL's Operating Margin % is ranked lower than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. NAS:OCUL: -2296.03 )
Ranked among companies with meaningful Operating Margin % only.
NAS:OCUL' s Operating Margin % Range Over the Past 10 Years
Min: -136710  Med: -2902.81 Max: -2182.69
Current: -2296.03
-136710
-2182.69
Net Margin % -2369.00
NAS:OCUL's Net Margin % is ranked lower than
84% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. NAS:OCUL: -2369.00 )
Ranked among companies with meaningful Net Margin % only.
NAS:OCUL' s Net Margin % Range Over the Past 10 Years
Min: -140930  Med: -3039.94 Max: -2271.31
Current: -2369
-140930
-2271.31
ROE % -63.05
NAS:OCUL's ROE % is ranked lower than
67% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. NAS:OCUL: -63.05 )
Ranked among companies with meaningful ROE % only.
NAS:OCUL' s ROE % Range Over the Past 10 Years
Min: -63.14  Med: -58.38 Max: -53.61
Current: -63.05
-63.14
-53.61
ROA % -48.81
NAS:OCUL's ROA % is ranked lower than
65% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. NAS:OCUL: -48.81 )
Ranked among companies with meaningful ROA % only.
NAS:OCUL' s ROA % Range Over the Past 10 Years
Min: -59.94  Med: -55.74 Max: -42.17
Current: -48.81
-59.94
-42.17
ROC (Joel Greenblatt) % -1303.02
NAS:OCUL's ROC (Joel Greenblatt) % is ranked lower than
65% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. NAS:OCUL: -1303.02 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:OCUL' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2049.81  Med: -1559.32 Max: -1303.02
Current: -1303.02
-2049.81
-1303.02
GuruFocus has detected 4 Warning Signs with Ocular Therapeutix Inc $NAS:OCUL.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:OCUL's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

OCUL Guru Trades in Q1 2016

Paul Tudor Jones Sold Out
» More
Q2 2016

OCUL Guru Trades in Q2 2016

Jim Simons 47,300 sh (New)
» More
Q3 2016

OCUL Guru Trades in Q3 2016

Jim Simons Sold Out
» More
Q4 2016

OCUL Guru Trades in Q4 2016

Jim Simons 145,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:OCUL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:PRMCF, NAS:CYAD, OTCPK:TYMI, NAS:KMDA, OTCPK:SIGA, AMEX:MTNB, OTCPK:RCAR, OTCPK:CLVLF, NAS:EDGE, NAS:AVXL, NAS:SELB, NAS:DVAX, OTCPK:ELVAF, OTCPK:OXBDF, NAS:CGEN, NAS:PTGX, NAS:VTVT, NAS:STML, NAS:TRVN, NAS:NK » details
Traded in other countries:0OT.Germany,
Headquarter Location:USA
Ocular Therapeutix Inc is a biopharmaceutical company developing and commercializing therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology.

Ocular Therapeutix is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application.

Ratios

vs
industry
vs
history
PB Ratio 4.79
OCUL's PB Ratio is ranked lower than
58% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. OCUL: 4.79 )
Ranked among companies with meaningful PB Ratio only.
OCUL' s PB Ratio Range Over the Past 10 Years
Min: 1.54  Med: 4.08 Max: 17.67
Current: 4.79
1.54
17.67
PS Ratio 129.36
OCUL's PS Ratio is ranked lower than
87% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. OCUL: 129.36 )
Ranked among companies with meaningful PS Ratio only.
OCUL' s PS Ratio Range Over the Past 10 Years
Min: 59.86  Med: 133.68 Max: 1057.5
Current: 129.36
59.86
1057.5
EV-to-EBIT -5.51
OCUL's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. OCUL: -5.51 )
Ranked among companies with meaningful EV-to-EBIT only.
OCUL' s EV-to-EBIT Range Over the Past 10 Years
Min: -31.3  Med: -4.6 Max: -0.9
Current: -5.51
-31.3
-0.9
EV-to-EBITDA -5.62
OCUL's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. OCUL: -5.62 )
Ranked among companies with meaningful EV-to-EBITDA only.
OCUL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -32  Med: -4.7 Max: -0.9
Current: -5.62
-32
-0.9
Current Ratio 8.42
OCUL's Current Ratio is ranked higher than
73% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. OCUL: 8.42 )
Ranked among companies with meaningful Current Ratio only.
OCUL' s Current Ratio Range Over the Past 10 Years
Min: 5.39  Med: 8.42 Max: 19.89
Current: 8.42
5.39
19.89
Quick Ratio 8.41
OCUL's Quick Ratio is ranked higher than
73% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. OCUL: 8.41 )
Ranked among companies with meaningful Quick Ratio only.
OCUL' s Quick Ratio Range Over the Past 10 Years
Min: 5.39  Med: 8.41 Max: 19.87
Current: 8.41
5.39
19.87
Days Inventory 106.95
OCUL's Days Inventory is ranked higher than
58% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. OCUL: 106.95 )
Ranked among companies with meaningful Days Inventory only.
OCUL' s Days Inventory Range Over the Past 10 Years
Min: 101.76  Med: 152.75 Max: 266.73
Current: 106.95
101.76
266.73
Days Sales Outstanding 48.36
OCUL's Days Sales Outstanding is ranked higher than
61% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. OCUL: 48.36 )
Ranked among companies with meaningful Days Sales Outstanding only.
OCUL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 40.25  Med: 101.96 Max: 1642.5
Current: 48.36
40.25
1642.5
Days Payable 1.00
OCUL's Days Payable is ranked lower than
99% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. OCUL: 1.00 )
Ranked among companies with meaningful Days Payable only.
OCUL' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 3758.83 Max: 30399.29
Current: 1
1
30399.29

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 5.50
OCUL's Price-to-Net-Cash is ranked higher than
60% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. OCUL: 5.50 )
Ranked among companies with meaningful Price-to-Net-Cash only.
OCUL' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.75  Med: 4.62 Max: 9.08
Current: 5.5
2.75
9.08
Price-to-Net-Current-Asset-Value 5.30
OCUL's Price-to-Net-Current-Asset-Value is ranked higher than
60% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. OCUL: 5.30 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
OCUL' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.68  Med: 4.45 Max: 8.84
Current: 5.3
2.68
8.84
Price-to-Tangible-Book 4.79
OCUL's Price-to-Tangible-Book is ranked higher than
51% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. OCUL: 4.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
OCUL' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.59  Med: 4.03 Max: 8.55
Current: 4.79
2.59
8.55
Price-to-Median-PS-Value 0.97
OCUL's Price-to-Median-PS-Value is ranked higher than
62% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. OCUL: 0.97 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
OCUL' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.81  Med: 0.91 Max: 2.79
Current: 0.97
0.81
2.79
Earnings Yield (Greenblatt) % -18.17
OCUL's Earnings Yield (Greenblatt) % is ranked lower than
75% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. OCUL: -18.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
OCUL' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -26.3  Med: 0 Max: 547.73
Current: -18.17
-26.3
547.73

More Statistics

Revenue (TTM) (Mil) $1.89
EPS (TTM) $ -1.80
Short Percentage of Float34.33%
52-Week Range $4.04 - 13.46
Shares Outstanding (Mil)29.03

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 30 58
EPS ($) -1.70 -1.33
EPS without NRI ($) -1.70 -1.33
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:OCUL

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

More From Other Websites
ETFs with exposure to Ocular Therapeutix, Inc. : April 24, 2017 Apr 24 2017
Ocular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for... Apr 24 2017
Ocular Therapeutix™ Appoints George Migausky as Interim Chief Financial Officer Apr 06 2017
Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017 Mar 20 2017
Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study Mar 17 2017
Why Ocular Therapeutix Inc Saw its Share Price Jump Today Mar 16 2017
Ocular's Dextenza Reports Positive Study Results Mar 16 2017
After setback, Bedford eye care biotech has its sights set on FDA approval Mar 15 2017
New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™... Mar 15 2017
Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017 Mar 14 2017
Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT Mar 10 2017
Ocular Therapeutix reports 4Q loss Mar 10 2017
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results Mar 10 2017
Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results Mar 08 2017
Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS) Feb 23 2017
Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for... Feb 23 2017
Ocular Therapeutix™ Announces FDA Acceptance of NDA Resubmission for DEXTENZA™ for the Treatment... Feb 22 2017
Why Ocular Therapeutix Inc Jumped Higher Today Feb 10 2017
Ocular TherapeutixTM to Present at Three Upcoming Investor Conferences Feb 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)